European Pharmaceutical Sector Faces Challenges from US Policies and China's Biotech Growth

Europe's pharmaceutical sector has long dealt with structural challenges that hinder its competitiveness. Companies have cited fragmented capital markets, inconsistent adoption of single-market rules for pricing and clinical trials, and varying reimbursement policies across member states as key obstacles.

These factors have limited access to funding and increased operational complexities for drug development and market entry.

CNBC reported that policies implemented during the Trump administration in the US have accelerated changes in the global pharmaceutical landscape. These policies included efforts to reduce regulatory burdens and promote domestic manufacturing, which shifted investment and innovation away from Europe.

The report highlighted how such measures have made the US a more attractive destination for biotech investments.

biotech sector has experienced significant growth in recent years, with increased investments in research and development.

According to CNBC, this boom is driven by government support and a growing domestic market, positioning China as a major player in pharmaceuticals. European companies face heightened competition from Chinese firms in areas such as generic drugs and innovative therapies. The combination of US policy shifts and China's advancements has impacted Europe's status as a pharma powerhouse.

Historically, Europe hosted leading companies and research institutions, but current trends indicate a redistribution of global resources. Stakeholders, including industry groups, have noted that these external pressures exacerbate internal European challenges.

The stakes involve Europe's ability to retain talent, secure funding, and maintain market share in a global industry valued at hundreds of billions of dollars.